Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lusher

Showing results (11-20 of 177) with videos related to

Pageof 18
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Considerations for current and future management of haemophilia and its complicationsJ M Lusher
Journal of Thrombosis and Haemostasis : JTH|May 14, 2004
Is the incidence and prevalence of inhibitors greater with recombinant products? NoJ M Lusher
European Journal of Haematology. Supplementum|January 12, 1999
Early treatment with recombinant factor VIIa results in greater efficacy with less productJ M Lusher
Haemostasis|January 1, 1996
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitorsJ M Lusher
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 24, 1999
Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP--a survey of European physiciansJ M Lusher
Progress in Clinical and Biological Research|January 1, 1984
Assessment of response to treatment and design of clinical trialsJ M Lusher
Progress in Clinical and Biological Research|January 1, 1984
Controlled clinical trials with prothrombin complex concentratesJ M Lusher
Thrombosis and Haemostasis|December 22, 1999
Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cureJ M Lusher
Paleopathology Newsletter|June 1, 1975
Bone changes in sickle cell diseaseJ M Lusher
Seminars in Thrombosis and Hemostasis|July 5, 2002
First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor developmentJeanne M Lusher
Pageof 18

Showing results (11-20 of 177) with videos related to

Sort By:
Pageof 18
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Considerations for current and future management of haemophilia and its complicationsJ M Lusher
Journal of Thrombosis and Haemostasis : JTH|May 14, 2004
Is the incidence and prevalence of inhibitors greater with recombinant products? NoJ M Lusher
European Journal of Haematology. Supplementum|January 12, 1999
Early treatment with recombinant factor VIIa results in greater efficacy with less productJ M Lusher
Haemostasis|January 1, 1996
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitorsJ M Lusher
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 24, 1999
Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP--a survey of European physiciansJ M Lusher
Progress in Clinical and Biological Research|January 1, 1984
Assessment of response to treatment and design of clinical trialsJ M Lusher
Progress in Clinical and Biological Research|January 1, 1984
Controlled clinical trials with prothrombin complex concentratesJ M Lusher
Thrombosis and Haemostasis|December 22, 1999
Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cureJ M Lusher
Paleopathology Newsletter|June 1, 1975
Bone changes in sickle cell diseaseJ M Lusher
Seminars in Thrombosis and Hemostasis|July 5, 2002
First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor developmentJeanne M Lusher
Pageof 18